Exclusive GPs have been told to ignore current NICE lipid modification guidelines on statin prescribing in low-risk people, under a cost-saving policy at one CCG.
NHS Stockport CCG has advised GPs should only prescribe statins to people if they are found to be at a 20% or greater risk of cardiovascular disease – and not at the lower NICE-recommended threshold of 10%-20%.
The CCG has also stipulated that GPs should prescribe simvastatin first-line rather than the NICE-recommended lipid-lowering drug atorvastatin, as part of measures to control spending.
NICE condemned the decision, which it said meant people were being denied the opportunity to lower their risk of a disease that ‘maims and kills one in three’.
The GPC said that the CCG’s decision was ‘strange’ and ‘born out of desperation’.
A recent prescribing news bulletin from the CCG said it had ‘made the decision not to implement the NICE Lipid Modification Guidelines 2014’, adding: ‘We recommend that patients should be treated if their CVD risk is 20% or above and first line treatment should be with simvastatin 40mg.’
The NICE guidelines state that GPs should offer patients the option of a statin if their 10-year risk of cardiovascular disease is 10% or higher and recommend treatment with atorvastatin as the most effective treatment option because it is ‘more potent than simvastatin and less likely to interact with other drugs, as well as being easier for patients to take’ .
In a statement to Pulse, NHS Stockport CCG said the decision to block the updated NICE guidance was part of a wider strategy to balance finances.
It said: ‘The CCG was required to make some decisions on savings to achieve financial balance and long term financial health. The plan included a decision to not implement the NICE lipid modification guidelines for primary prevention (CG181) in full.
‘There were extensive clinical conversations at the CCG between the guidelines being issued and the decision in March 2015.’
The statement added that GPs should follow NICE advice around lifestyle modifications – such as diet and exercise – in low-risk patients, but that ‘there is a process to follow for clinical exceptionality and this would be the case for patients where lifestyle modification is ineffective or inappropriate’.
Regarding the advice on what lipid-lowering drug, the CCG said: ‘The decision to recommend simvastatin over atorvastatin was made on clinical cost effectiveness grounds.’
Dr Andrew Green, chair of the GPC’s clinical and prescribing subcommittee questioned the CCG’s rationale for controlling statin prescribing and warned GPs must still pay attention to the full NICE guidelines.
Dr Green said: ‘So many CCGs are in deficit due to underfunding, and the pressure on them to achieve financial balance is so great, that we are beginning to see some very strange decisions born out of desperation.’
Dr Green added that ‘the difference in price between simvastatin and atorvastatin is so low that it would be very difficult to justify not implementing NICE guidance about choice of statin, and GPs need to remember that they have responsibility for their prescribing decisions’.
Professor Mark Baker, director of the centre for clinical practice at NICE said: ‘Cardiovascular disease maims and kills people through coronary heart disease, peripheral arterial disease and stroke. Together, these kill one in three of us.
‘This decision amounts to denying patients access to the most effective means of reducing that risk. The overwhelming body of evidence supports the use of statins, even in people at low risk of cardiovascular disease. It clearly shows statins are safe and clinically and cost effective for use in people with a 10% risk of CVD over 10 years.
‘Our guidance is intended to prevent many lives being destroyed and it offers a major shift in public health outcomes at relatively low cost. In doing so it places patients, not the cost of treatment, centrally in any decision making about their management.’
The row over the 10% threshold
Simvastatin – Statin – Cardiovascular – Online
Source: Julian Claxton
NICE’s decision to recommend prescribing statins to people at the lower 10% risk threshold led to outcry from GP leaders when the guidelines were updated two years ago.
The GPC was among the dissenters, who warned the recommendation could lead to overmedicalisation and divert GPs’ precious resources away from their chronically ill patients onto healthier ‘worried well’ people.
NICE had recommended that GP practices should be incentivised through QOF for statin prescribing at the 10% primary prevention risk threshold in all patients newly diagnosed with diabetes or hypertension.
However, it later rolled back on the recommendation.